A centrally-acting desire stack built on PT-141 (bremelanotide), with an optional PDE5 inhibitor for the physical side.
PT-141 (bremelanotide) works centrally on melanocortin pathways to raise sexual desire — a different mechanism from the blood-flow-focused PDE5 inhibitors, and FDA-approved for women with hypoactive sexual desire disorder. It's the anchor here for libido as distinct from erectile function.
Tadalafil is an optional add-on for the physical/erectile side via the PDE5 route — long-acting and well understood. Combining a central desire agent with a peripheral blood-flow agent is a deliberate two-mechanism approach; start each separately to learn your own tolerance before combining.
| Compound | Role | Dose | Frequency |
|---|---|---|---|
| PT-141 Central melanocortin desire agent; max one dose/24h. | Primary | Start 0.5mg test dose; typical 1–1.75mg as needed | As needed before sexual activity; max 1 dose per 24 hours |
| Tadalafil Optional long-acting PDE5 inhibitor for the physical side. | Optional | 5mg daily or 10-20mg as-needed | Once daily or as-needed (max once per 24 hours) |